Companies › Sirius Therapeutics
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Cardiovascular; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SRSD107 siRNA-based anticoagulant | – | Phase 2 | Venous Thromboembolism; Coronary Artery Disease (CAD) | Dec 2027 |
| SRSD216 | – | Phase 1 | Hyperlipoproteinemia (a) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07140523 | SRSD107 | Phase 2 | Venous Thromboembolism | Cardiovascular | Jun 2026 |
| NCT07172646 | SRSD216 | Phase 1 | Hyperlipoproteinemia (a) | Metabolic and endocrine | Apr 2027 |
| NCT07318155 | SRSD107 | Phase 2 | Coronary Artery Disease (CAD) | Cardiovascular | Dec 2027 |
No annotated target.
–
Vincentage Pharma Shanghai Minwei Biotechnology HELP Therapeutics Crystalys Therapeutics Biomea Fusion
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.